$1.28
▲ +1.2% Today
as of Jul 22, 16:45 ET
Last 30 days
Recent Press Releases & News
Actuate Therapeutics Says Elraglusib to be Evaluated in Phase 1/2 Trial to Find Treatments for Pediatric Neuroblastoma
Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma
Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer
Overview
52-week range
$1.58
$9.35
0% of range
Avg surprise (last 3)
-28.4%
Avg reaction (last 2)
-0.6%
50% positive
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 14, 2026 | Mar/2026 | $-0.24 | $-0.23 | -4.3% | +25.0% | -2.4% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.25 | — | — | — | — | financials |
| Thu Aug 14, 2025 | Jun/2025 | $-0.30 | $-0.19 | -57.9% | — | — | earnings |
| Thu May 15, 2025 | Mar/2025 | $-0.32 | $-0.26 | -23.1% | — | +1.1% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.55 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-4.20 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-5.40 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-4.31 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-3.88 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 13, 2026 | Jun/2026 | OTHER | -$0.20 | -$0.30 | +33.3% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-6M | — | $-5M | $-6M | $-6M | — | $-5M | $-5M |
| Net income | $-6M | — | $-5M | $-6M | $-6M | — | $-6M | $-7M |
| EPS (diluted) | $-0.24 | — | $-0.25 | $-0.30 | $-0.32 | — | $-0.55 | $-4.20 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $8M | — | $17M | $6M | $4M | — | $14M | $351,709 |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $9M | $14M | $17M | $7M | $4M | $9M | $14M | $549,687 |
| Total assets | $9M | $14M | $18M | $7M | $4M | $9M | $14M | $2M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $5M | $6M | $7M | $10M | $10M | $9M | $9M | $22M |
| Total equity | $4M | $8M | $11M | $-3M | $-5M | $104,186 | $5M | $-114M |
Implied volatility — last 90 days
No IV snapshots yet for ACTU.
IV is captured twice daily (9:15 AM & 4:30 PM ET) for tickers with upcoming earnings. Comes online automatically once the next options refresh runs.